175 related articles for article (PubMed ID: 33371576)
1. Food and Dietary Supplement Package Labeling-Guidance from FDA's Warning Letters and Title 21 of the Code of Federal Regulations.
Brody T
Compr Rev Food Sci Food Saf; 2016 Jan; 15(1):92-129. PubMed ID: 33371576
[TBL] [Abstract][Full Text] [Related]
2. Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events.
Li W; Wertheimer A
Innov Pharm; 2023; 14(1):. PubMed ID: 38035313
[No Abstract] [Full Text] [Related]
3. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
4. FDA's review of scientific evidence for health claims.
Schneeman B
J Nutr; 2007 Feb; 137(2):493-4. PubMed ID: 17237334
[TBL] [Abstract][Full Text] [Related]
5. Dietary supplement labeling and advertising claims: are clinical studies on the full product required?
Villafranco JE; Bond K
Food Drug Law J; 2009; 64(1):43-67. PubMed ID: 19998572
[TBL] [Abstract][Full Text] [Related]
6. Status of nutrition labeling, health claims, and nutrient content claims for processed foods: 1997 Food Label and Package Survey.
Brecher SJ; Bender MM; Wilkening VL; McCabe NM; Anderson EM
J Am Diet Assoc; 2000 Sep; 100(9):1057-62. PubMed ID: 11019354
[TBL] [Abstract][Full Text] [Related]
7. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
[No Abstract] [Full Text] [Related]
8. A review of US EPA and FDA requirements for electronic records, electronic signatures, and electronic submissions.
Keatley KL
Qual Assur; 1999; 7(2):77-89. PubMed ID: 10992873
[TBL] [Abstract][Full Text] [Related]
9. Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.
Wang L; Zheng H; Ren X; Sun H
Ther Innov Regul Sci; 2016 May; 50(3):312-318. PubMed ID: 30227064
[TBL] [Abstract][Full Text] [Related]
10. The importance of GRAS to the functional food and nutraceutical industries.
Burdock GA; Carabin IG; Griffiths JC
Toxicology; 2006 Apr; 221(1):17-27. PubMed ID: 16483705
[TBL] [Abstract][Full Text] [Related]
11. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings.
Tucker J; Fischer T; Upjohn L; Mazzera D; Kumar M
JAMA Netw Open; 2018 Oct; 1(6):e183337. PubMed ID: 30646238
[TBL] [Abstract][Full Text] [Related]
12. Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.
Bai HK; Ahearn JD; Bartlett MG
Ther Innov Regul Sci; 2021 Mar; 55(2):426-436. PubMed ID: 33095420
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation.
Chaloupka FJ; Warner KE; Acemoğlu D; Gruber J; Laux F; Max W; Newhouse J; Schelling T; Sindelar J
Tob Control; 2015 Mar; 24(2):112-9. PubMed ID: 25550419
[TBL] [Abstract][Full Text] [Related]
14. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
15. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2020 Jul; 54(4):925-931. PubMed ID: 32557315
[TBL] [Abstract][Full Text] [Related]
16. FDA perspectives on health claims for food labels.
Rowlands JC; Hoadley JE
Toxicology; 2006 Apr; 221(1):35-43. PubMed ID: 16480811
[TBL] [Abstract][Full Text] [Related]
17. FDA regulation of dietary supplements and requirements regarding adverse event reporting.
Frankos VH; Street DA; O'Neill RK
Clin Pharmacol Ther; 2010 Feb; 87(2):239-44. PubMed ID: 20032973
[TBL] [Abstract][Full Text] [Related]
18. Label claims for foods and supplements: a review of the regulations.
Turner RE; Degnan FH; Archer DL
Nutr Clin Pract; 2005 Feb; 20(1):21-32. PubMed ID: 16207644
[TBL] [Abstract][Full Text] [Related]
19. FDA actions against health economic promotions, 2002-2011.
Neumann PJ; Bliss SK
Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
[TBL] [Abstract][Full Text] [Related]
20. What makes consumers think dietary supplements are safe and effective? The role of disclaimers and FDA approval.
Dodge T; Kaufman A
Health Psychol; 2007 Jul; 26(4):513-7. PubMed ID: 17605572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
